Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer

• Status: Unknown status
• Trial end date: 1969-12-31

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known which regimen of combination chemotherapy given together with trastuzumab is most effective in treating breast cancer.

PURPOSE: This randomized phase III trial is comparing two different regimens of combination chemotherapy given together with trastuzumab to see how well they work in treating women with HER2-positive stage I, stage II, or stage III breast cancer.

• Phase: Phase 3

Details

• Lead Sponsor: Azienda Ospedaliera - Universitaria di Modena; Azienda Ospedaliero-Universitaria di Modena
• Treatments: Aromatase Inhibitors; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Fluorouracil; Hormones; Liposomal doxorubicin; Tamoxifen; Trastuzumab